Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Centanafadine - Otsuka Pharmaceutical

Drug Profile

Centanafadine - Otsuka Pharmaceutical

Alternative Names: Centanafadine SR; CTN SR; EB-1020; EB-1020 SR

Latest Information Update: 31 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Euthymics Bioscience
  • Developer Euthymics Bioscience; Otsuka Pharmaceutical
  • Class Azabicyclo compounds; Behavioural disorder therapies; Cyclohexanes; Naphthalenes; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • No development reported Major depressive disorder; Neuropathic pain

Most Recent Events

  • 31 Mar 2021 Chemical structure information added
  • 09 Mar 2021 Otsuka Phamraceutical initiates enrolment in a phase I trials in Attention-deficit hyperactivity disorder (In children) in USA (PO) (NCT04786730)
  • 08 Mar 2021 Otsuka Pharmaceutical plans a phase I trial for Attention-deficit hyperactivity disorder (In children) (PO, Capsule) March 2021 (NCT04786730)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top